Kanamycin

CHEMBL1384 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
484.5 g/mol
LogP
-6.9
Phase
4

An aminoglycoside antibiotic used to treat serious bacterial infections including tuberculosis, working by binding to bacterial ribosomes to inhibit protein synthesis. It has also been studied as an inhaled therapy for asthma-related bacterial infections.

น้ำหนักโมเลกุล

484.5000 g/mol

LogP

-6.90

TPSA

283.00 Ų

Lipinski RO5

ไม่ผ่าน

ด้านการรักษา

กลไกการออกฤทธิ์

Binds irreversibly to the 30S ribosomal subunit, causing misreading of mRNA codons and inhibition of translocation. This leads to production of aberrant proteins and disruption of the bacterial cell membrane.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Binds irreversibly to the 30S ribosomal subunit, causing misreading of mRNA codons and inhibition of translocation. This leads to production of aberrant proteins and disruption of the bacterial cell membrane.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

NC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H](N)C[C@@H]2N)[C@H](O)[C@@H](O)[C@@H]1O

InChI

InChI=1S/C18H36N4O11/c19-2-6-10(25)12(27)13(28)18(30-6)33-16-5(21)1-4(20)15(14(16)29)32-17-11(26)8(22)9(24)7(3-23)31-17/h4-18,23-29H,1-3,19-22H2/t4-,5+,6-,7-,8+,9-,10-,11-,12+,13-,14-,15+,16-,17-,18-/m1/s1

Molecular Formula

C18H36N4O11

HBD / HBA

11 / 15

พันธะที่หมุนได้

6

อะตอมหนัก

33

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

An aminoglycoside antibiotic used to treat serious bacterial infections including tuberculosis, working by binding to bacterial ribosomes to inhibit protein synthesis. It has also been studied as an inhaled therapy for asthma-related bacterial infections.

Binds irreversibly to the 30S ribosomal subunit, causing misreading of mRNA codons and inhibition of translocation. This leads to production of aberrant proteins and disruption of the bacterial cell membrane.

Yes, Kanamycin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1384. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 6032. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.